PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
San Francisco- and Boston-based PEAR Therapeutics, a developer of software being used to treat substance use disorders, has raised $50M in a Series B funding round, the company said today. The funding was led by Temasek, and also included 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder's Collaborative. PEAR Therapeutics says it has created "prescription digital therapeutics" for treating sustance abuse; the company also is working on "digital therapeutics" for treating schizophrenia, and a virtual reality app use to treat post traumatic stress disorder (PTSD). Corey McCann is President and CEO of PEAR Therapeutics.
posted on Tuesday, January 2, 2018 (Link to more information)
Related companies:
Pear Deck, Inc.
Related stories:
> Protagonist Therapeutics Gains $40M
> Hyperion Therapeutics Raises $60M
> Oraya Therapeutics Raises $15.875M
> Merck Buys Sirna Therapeutics
> Nuon Therapeutics Raises $27M
silicontap.com Home